The company discussed its efforts to grow adoption of its products during a call to discuss second quarter financial results for fiscal year 2018.
Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.
The firm reported total revenues of $194 million, compared to $196.5 million in Q2 2017, but beat the consensus Wall Street estimate of $188.8 million.
The genetic testing firm can now offer its Prelude noninvasive prenatal test to residents in New York State.
The FDA has expanded the indications for both AstraZeneca's PARP inhibitor Lynparza and Myriad Genetics' BRACAnalysis CDx test, as GenomeWeb reports.
Myriad Genetics' BRACAnalysis CDx can identify which metastatic patients have BRCA mutations and would likely benefit from treatment with AstraZeneca's Lynparza.
Several of the top molecular diagnostic firms presented at the JP Morgan Healthcare Conference on Monday discussing product portfolios, FDA clearances, and plans for 2018.
Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.
The drugmaker will use Myriad's expanded molecular diagnostic panel to evaluate best responders to a combination of Lynparza and Avastin in clinical trials.
Technology Review reports on Myriad Genetics' polygenic risk score for breast cancer.
The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.
Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.
Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.
In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.